TPO and neoplasm: The strengths of the subcutaneous tumor models coupled with the rapidly penetrant phenotype of our de novo BrafV600E+/−/Pten+/−/TPO-Cre murine model [30,31] led us to develop a syngeneic tumor model of PTC.